Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440973 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00440973 is a Phase 2 study that was terminated before completion, run by The Methodist Hospital Research Institute. The registered enrollment target is 6 participants.
The verdict
NCT00440973, a Phase 2 study, was terminated before completion, sponsored by The Methodist Hospital Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and disease progression, decrease tumor size, as well as determine if the combination therapy is safer and less toxic than the standard treatment for renal cell carcinoma.
Interventions
- DRUG Bevacizumab
- DRUG Interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440973
The ClinicalTrials.gov registry entry for NCT00440973 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00440973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00440973 about?
NCT00440973 is a clinical study titled "Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer". The purpose of this study is to determine if the combination of therapy to strengthen the immune system (Interleukin - 2) plus a specific tumor target therapy (Bevacizumab) can prolong the time between the start of treatment and disease progression, decrease tumor size, as well as determine if the c...
What is the current status of trial NCT00440973?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2006-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00440973?
The interventions under investigation include: Bevacizumab (DRUG), Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT00440973?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.